By: on In Gout News

Can Gout Meds Decrease Diabetes Complications?


New research has revealed that a medicine used to help with gout, referred to as colchicine, can assist with the diabetes complication known as metabolic syndrome.

Medical News Bulletin reported that about one-third of U.S.

adults suffer from the illness that is outlined by a combination of other conditions like increased body fat, high blood sugar and blood pressure, as well as increased triglyceride and cholesterol levels. Together, these can enhance chances of type 2 diabetes, stroke, and heart disease.

While metabolic syndrome is linked heavily to lack of activity and obesity, it can also be connected to insulin resistance that can result in increased levels of blood sugar. The chances around metabolic syndrome can enhance with aging, and the following: ethnicity (U.S. Hispanic females are at the greatest risk), along with diabetes, and obesity. The best way to prevent this condition is focusing on a positive lifestyle changes by keeping a healthy weight, maintaining an exercise routine, eating a balanced diet, and not smoking.

A research team from the National Institutes of Health recently published a study that outlined how the colchicine medicine, used primarily for gout, could help with metabolic syndrome complications, as it prevents the formation around a massive protein complex that triggers inflammation due to obesity.

Studies in the past have revealed that obesity can help bring on type 2 diabetes, so the researchers believed that colchicine might be able to assist in preventing this condition within obese individuals, by preventing the inflammation.

The study randomly assigned 21 participants, and they were given colchicine two times daily, for three months; meanwhile, 19 participants were given placebo. The study’s main focus was to see how insulin worked to clear up sugar from the blood, where the team also reviewed other markers for inflammation and variables around metabolism.

While no difference was found when it came to both groups around insulin use, improvement was seen in the colchicine participants when it came to the Homeostatic Model Assessment of Insulin Resistance test; which also figures out the amount of insulin required to keep blood sugar at normal level when fasting. Additionally, the colchicine group had lower scores when it came to a C-reactive protein blood test, and other tests around inflammation.

While this does provide plenty of hope, the team did note that more research is needed, within a larger study scope, to help conclude that colchicine could prevent type 2 diabetes complications among those with metabolic syndrome.